| Literature DB >> 36105581 |
Bing Kang1,2, Zhi-Qiang Zhao3, Xiao-Yu Liu1, Yu-Xi Cheng1, Wei Tao1, Zheng-Qiang Wei1, Dong Peng1.
Abstract
Purpose: The purpose of our study was to investigate the effect of pre-operative hypoalbuminemia on the short-term outcomes after primary colorectal cancer (CRC) surgery. Materials and methods: The retrospective study enrolled CRC patients who underwent primary surgery from January 2011 to December 2021 in a single teaching hospital. The short-term outcomes were compared between the hypoalbuminemia group and the normal group using propensity score matching (PSM). Univariate and multivariate logistic regression analyses were used for analyzing independent predictors of overall complications and major complications.Entities:
Keywords: colorectal cancer; complications; hypoalbuminemia; outcomes; surgery
Year: 2022 PMID: 36105581 PMCID: PMC9464913 DOI: 10.3389/fnut.2022.925086
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
FIGURE 1Flow chart of patient selection.
Baseline characteristics before and after PSM.
| Characteristics | Before PSM | After PSM | ||||
| Hypoalbuminemia (1078) | Normal (5994) | Hypoalbuminemia (1028) | Normal (1028) | |||
| Albumin | 31.0 ± 3.1 | 41.3 ± 4.2 | <0.01 | 31.1 ± 3.0 | 39.8 ± 4.3 | <0.01 |
| Age (year) | 67.8 ± 12.4 | 61.9 ± 12.1 | <0.01 | 67.5 ± 12.4 | 67.7 ± 11.6 | 0.753 |
| Sex | 0.993 | 0.964 | ||||
| Male | 632 (58.6%) | 3515 (58.6%) | 601 (58.5%) | 602 (58.6%) | ||
| Female | 446 (41.4%) | 2479 (41.4%) | 427 (41.5%) | 426 (41.4%) | ||
| BMI (kg/m2) | 21.6 ± 3.3 | 22.8 ± 3.1 | <0.01 | 21.6 ± 3.3 | 21.7 ± 3.0 | 0.661 |
| Smoking | 410 (38.0%) | 2226 (37.1%) | 0.575 | 399 (38.8%) | 394 (38.3%) | 0.821 |
| Drinking | 327 (30.3%) | 1832 (30.6%) | 0.880 | 314 (30.5%) | 311 (30.3%) | 0.886 |
| Hypertension | 287 (26.6%) | 1500 (25.0%) | 0.266 | 272 (26.5%) | 273 (26.6%) | 0.960 |
| T2DM | 139 (12.9%) | 668 (11.1%) | 0.096 | 132 (12.8%) | 138 (13.4%) | 0.695 |
| CHD | 77 (7.1%) | 241 (4.0%) | <0.01 | 74 (7.2%) | 68 (6.6%) | 0.602 |
| CKD | 199 (18.5%) | 1027 (17.1%) | 0.290 | 190 (18.5%) | 201 (19.6%) | 0.536 |
| CLD | 27 (2.5%) | 189 (3.2%) | 0.255 | 27 (2.6%) | 26 (2.5%) | 0.889 |
| Surgical history | 273 (25.3%) | 1472 (24.6%) | 0.591 | 256 (24.9%) | 277 (26.9%) | 0.291 |
| Laparoscopy | 790 (73.3%) | 5381 (89.8%) | <0.01 | 777 (75.6%) | 769 (74.8%) | 0.683 |
| Hemoglobin, g/L | 103.3 ± 22.9 | 124.3 ± 22.7 | <0.01 | 104.6 ± 22.4 | 104.4 ± 24.4 | 0.908 |
| Lymphocyte, 109 | 1.2 ± 0.5 | 1.5 ± 0.6 | <0.01 | 1.2 ± 0.5 | 1.2 ± 0.5 | 0.720 |
| Tumor size | <0.01 | 0.505 | ||||
| <5 cm | 449 (41.7%) | 3820 (63.7%) | 439 (42.7%) | 454 (44.2%) | ||
| ≥5 cm | 629 (58.3%) | 2174 (36.3%) | 589 (57.3%) | 574 (55.8%) | ||
| Tumor location | <0.01 | 0.430 | ||||
| Colon | 710 (65.9%) | 2625 (43.8%) | 666 (64.8%) | 683 (66.4%) | ||
| Rectum | 368 (34.1%) | 3369 (56.2%) | 362 (35.2%) | 345 (33.6%) | ||
| Tumor stage | <0.01 | 0.666 | ||||
| I | 119 (11.0%) | 1206 (20.1%) | 116 (11.3%) | 127 (12.4%) | ||
| II | 524 (48.6%) | 2307 (38.5%) | 495 (48.2%) | 468 (45.5%) | ||
| III | 375 (34.8%) | 2165 (36.1%) | 360 (35.0%) | 375 (36.5%) | ||
| IV | 60 (5.6%) | 316 (5.3%) | 57 (5.5%) | 58 (5.6%) | ||
Variables are expressed as the mean ± SD, n (%), *P-value < 0.05.
T2DM, type 2 diabetes mellitus; BMI, body mass index; PSM, propensity score matching; CHD, coronary heart disease; CKD, chronic kidney disease; CLD, chronic liver disease.
Short-term outcomes before and after PSM.
| Characteristics | Before PSM | After PSM | ||||
| Hypoalbuminemia (1078) | Normal (5994) | Hypoalbuminemia (1028) | Normal (1028) | |||
| Operation time (min) | 232.0 ± 88.1 | 225.2 ± 83.6 | 0.015 | 231.9 ± 88.3 | 220.9 ± 76.9 | 0.003 |
| Blood loss (mL) | 132.4 ± 229.4 | 99.7 ± 143.3 | <0.01 | 133.5 ± 233.3 | 113.9 ± 159.4 | 0.036 |
| Hospital stay (day) | 12.8 ± 8.6 | 10.9 ± 8.0 | <0.01 | 12.7 ± 8.6 | 11.4 ± 6.9 | <0.01 |
| Blood transfusion | 60 (5.6%) | 97 (1.6%) | <0.01 | 55 (5.4%) | 44 (4.3%) | 0.257 |
| Overall complications | 341 (31.6%) | 1168 (19.5%) | <0.01 | 323 (31.5%) | 263 (25.6%) | 0.003 |
| Major complications | 52 (4.8%) | 148 (2.5%) | <0.01 | 50 (4.9%) | 29 (2.8%) | 0.016 |
| 30-day death | 12 (1.1%) | 12 (0.2%) | <0.01 | 10 (1.0%) | 6 (0.6%) | 0.315 |
| Anastomotic leakage | 27 (2.5%) | 157 (2.6%) | 0.828 | 26 (2.5%) | 18 (1.8%) | 0.223 |
| Pneumonia | 80 (7.4%) | 143 (2.4%) | <0.01 | 75 (7.3%) | 39 (3.8%) | 0.001 |
| Wound infection | 52 (4.8%) | 189 (3.2%) | 0.005 | 49 (4.8%) | 41 (4.0%) | 0.388 |
| Lymphatic fistula | 10 (0.9%) | 32 (0.5%) | 0.121 | 10 (1.0%) | 8 (0.8%) | 0.636 |
| Intestinal obstruction | 22 (2.0%) | 115 (1.9%) | 0.789 | 22 (2.1%) | 22 (2.1%) | 1.000 |
| Venous thrombosis | 17 (1.6%) | 50 (0.8%) | 0.020 | 17 (1.7%) | 16 (1.6%) | 0.861 |
| Abdominal infection | 91 (8.4%) | 295 (4.9%) | <0.01 | 86 (8.4%) | 59 (5.7%) | 0.020 |
| Other complications | 100 (9.3%) | 393 (6.6%) | 0.001 | 95 (9.2%) | 99 (9.6%) | 0.763 |
Variables are expressed as the mean ± SD, n (%), *P-value < 0.05.
PSM, propensity score matching.
Univariate and multivariate logistic regression analysis of the overall complications.
| Risk factors | Univariate analysis | Multivariate analysis | ||
| OR (95% CI) | OR (95% CI) | |||
| Age, year | 1.031 (1.022–1.040) | <0.01 | 1.033 (1.023–1.043) | <0.01 |
| Surgical methods (open/laparoscopic) | 1.745 (1.410–2.158) | <0.01 | 1.631 (1.302–2.042) | <0.01 |
| Sex (male/female) | 0.887 (0.730–1.079) | 0.230 | ||
| BMI, Kg/m2 | 0.983 (0.953–1.013) | 0.267 | ||
| Hypertension (yes/no) | 1.236 (0.999–1.530) | 0.051 | ||
| T2DM (yes/no) | 1.727 (1.323–2.253) | <0.01 | 1.459 (1.105–1.927) | 0.008 |
| Surgical history (yes/no) | 1.188 (0.958–1.473) | 0.117 | ||
| Tumor location (colon/rectum) | 1.016 (0.830–1.243) | 0.877 | ||
| Tumor stage (IV/III/II/I) | 1.022 (0.901–1.159) | 0.737 | ||
| Smoking (yes/no) | 1.010 (0.830–1.229) | 0.922 | ||
| Drinking (yes/no) | 0.998 (0.811–1.230) | 0.988 | ||
| CHD (yes/no) | 1.543 (1.082–2.199) | 0.016 | 1.177 (0.811–1.710) | 0.391 |
| CKD (yes/no) | 1.503 (1.190–1.899) | 0.001 | 1.091 (0.846–1.405) | 0.503 |
| CLD (yes/no) | 1.539 (0.876–2.704) | 0.134 | ||
| Tumor size (≥5/<5), cm | 1.097 (0.904–1.332) | 0.348 | ||
| Albumin (hypoalbuminemia/normal), g/L | 1.333 (1.200–1.615) | 0.003 | 1.312 (1.075–1.602) | 0.008 |
| Hemoglobin, g/L | 0.997 (0.992–1.001) | 0.097 | ||
| Lymphocyte, 109 | 0.825 (0.676–1.007) | 0.058 | ||
| Blood loss, mL | 1.002 (1.001–1.002) | <0.01 | 1.001 (1.000–1.001) | 0.009 |
| Operation time, min | 1.003 (1.002–1.005) | <0.01 | 1.003 (1.002–1.004) | <0.01 |
*P-value < 0.05.
OR, odds ratio; CI, confidence interval; BMI, body mass index; T2DM, type 2 diabetes mellitus; CHD, coronary heart disease; CKD, chronic kidney disease; CLD, chronic liver disease.
Univariate and multivariate logistic regression analysis of the major complications.
| Risk factors | Univariate analysis | Multivariate analysis | ||
| OR (95% CI) | OR (95% CI) | |||
| Age, year | 1.031 (1.009–1.053) | 0.005 | 1.032 (1.010–1.054) | 0.004 |
| Surgical methods (open/laparoscopic) | 2.020 (1.271–3.210) | 0.003 | 2.284 (1.405–3.713) | 0.001 |
| Sex (male/female) | 0.812 (0.509–1.294) | 0.380 | ||
| BMI, Kg/m2 | 0.944 (0.876–1.016) | 0.124 | ||
| Hypertension (yes/no) | 1.004 (0.603–1.670) | 0.988 | ||
| T2DM (yes/no) | 0.845 (0.417–1.713) | 0.641 | ||
| Surgical history (yes/no) | 1.339 (0.824–2.174) | 0.238 | ||
| Tumor location (colon/rectum) | 0.582 (0.370–0.914) | 0.019 | 0.490 (0.306–0.785) | 0.003 |
| Tumor stage (IV/III/II/I) | 0.745 (0.551–1.006) | 0.055 | ||
| Smoking (yes/no) | 1.088 (0.530–1.322) | 0.718 | ||
| Drinking (yes/no) | 1.589 (1.044–2.516) | 0.048 | 1.648 (1.033–2.630) | 0.036 |
| CHD (yes/no) | 0.711 (0.256–1.972) | 0.512 | ||
| CKD (yes/no) | 1.366 (0.806–2.317) | 0.247 | ||
| CLD (yes/no) | 2.099 (0.738–5.967) | 0.164 | ||
| Tumor size (≥5/<5), cm | 0.914 (0.582–1.436) | 0.696 | ||
| Albumin (hypoalbuminemia/normal), g/L | 1.761 (1.105–2.806) | 0.017 | 1.787 (1.116–2.860) | 0.016 |
| Hemoglobin, g/L | 1.004 (0.994–1.013) | 0.451 | ||
| Lymphocyte, 109 | 0.599 (0.363–0.988) | 0.045 | 0.666 (0.408–1.086) | 0.103 |
| Blood loss, mL | 1.001 (1.000–1.001) | 0.050 | ||
| Operation time, min | 1.001 (0.997–1.002) | 0.747 | ||
*P-value < 0.05.
OR, odds ratio; CI, confidence interval; BMI, body mass index; T2DM, type 2 diabetes mellitus; CHD, coronary heart disease; CKD, chronic kidney disease; CLD, chronic liver disease.
Previous studies reporting the Hypoalbuminemia on the outcomes of CRC patients.
| Author | Year | Country | Sample size | Cut-off serum albumin (g/L) | Hypoalbuminemia group | Normal group | Patients | Outcomes |
| Lohsiriwat ( | 2007 | Thailand | 112 | 35 | 48 | 36 | Stage I–IV right-sided CC | Operative time, blood loss, complications, LOS |
| Lohsiriwat ( | 2008 | Thailand | 244 | 35 | 56 | 188 | Stage I–IV RC | Operative time, blood transfusion, complications, LOS |
| Sun ( | 2009 | China | 1,367 | 35 | 392 | 975 | Stage I–IV CRC | OS, CSS |
| Lai ( | 2011 | Taiwan | 3,732 | 35 | 693 | 3,039 | Stage I–III CC | OS, RFS, complications, mortality |
| Chandrasinghe ( | 2013 | Sri Lanka | 226 | 35 | 45 | 181 | Stage I–IV RC | OS |
| Ionescu ( | 2013 | Romania | 252 | 35 | 75 | 177 | Stage 0–IV CRC | Complications, LOS, mortality |
| Montomoli ( | 2015 | Denmark | 9,339 | 35 | 2,927 | 6,412 | Stage I–IV CRC | Mortality |
| Chiang ( | 2017 | Taiwan | 3,732 | 35 | 731 | 3,091 | Stage I–IV CRC | Complications, mortality |
| Hardt ( | 2017 | Germany | 370 | 35 | 67 | 303 | Stage 0–IV RC | Complications |
| Haskins ( | 2017 | United States | 5,143 | 35 | 746 | 4,397 | Stage I–III CC | Complications, mortality |
| Hu ( | 2019 | United States | 12,915 | 35 | 4,305 | 8,610 | Stage I–IV CRC | Complications, mortality (using PSM) |
| Almasaudi ( | 2020 | United Kingdom | 795 | 35 | 250 | 545 | Stage I–IV CRC | OS, CSS, complications |
| Sofić ( | 2021 | Germany | 107 | 35 | 75 | 32 | Stage I–IV CRC | Complications |
| Yang ( | 2021 | Taiwan | 106 | 35 | 23 | 83 | Stage I–III CRC | LOS |
CRC, colorectal cancer; RC, rectal cancer; CC, colon cancer; OS, overall survival; CSS, cancer-specific survival; RFS, relapse-free survival; DFS, disease-free survival; LOS, length of hospital stay; PSM, propensity score matching.